Citi Updates On VRUS

Citi has issued an update on Pharmasset Inc VRUS and ther final cure rate from the ph2 study. According to the report, "Pharmasset just announced the final cure rate (SVR24) from the ph 2 study in 25 pts who have genotype 2/3 type of hepC virus. Recall this represents 25-35% of all hepC pts globally and there is very little new competition to Pharmasset's PSI-7977 (nuc)." VRUS has a Buy Rating and has a $200 Price Target. VRUS closed at $129.39 a share yesterday.